The American Invents Act could have a big effect on the life sciences industry. Kevin Matha spoke with Robert A Armitage, senior vice president and general counsel at Eli Lilly, about the new legislative package
Tom Ciotti and Kate Murashige of Morrison & Foerster have been involved with the life sciences industry for almost 50 years. Phillip Bausk spoke with them about the changes they have seen in that time
Edward J Farrington of Inspicos considers the role of human intervention when acertaining the limits of patentability in plant breeding
Louise Tottie and Anette Romare of Valea outline important aspects of selection inventions relating to lists and ranges, to consider when drafting patent applications
Agustín Azcatl, Daniel Sánchez and Pedro Herrera of Olivares & Cia explain the impact of rule changes on first medical-use claims
Ha Kung Wong and John Kirkland of Fitzpatrick Cella Harper & Scinto use three scenarios to examine the impact of the Act and the future of paragraph IV litigation
Federal Circuit’s Brunetti ruling: barring immoral or scandalous marks is unconstitutional restriction of free spee… https://t.co/MivCKFINHg
Federal Circuit rules in Amgen v Sandoz on remand from SCOTUS https://t.co/uYIkfVhCHG https://t.co/2OZAscsz32
RT @mdloney: Canada moves closer to joining the Hague Agreement with the release of proposed new Industrial Design Regulations https://t.co…
End of Year 2017
Tribal sovereign immunity: Taking a wrecking ball to the IPR system
The lawyer behind Allergan’s controversial transfer of patents to a Native American tribe says others are “lining up to do deals”. But, Michael Loney asks, will the PTAB rule that sovereign immunity applies in these types of deals?
The material on this site is for financial institutions, professional investors
and their professional advisers. It is for information only. Please read our
Terms and Conditions
before using the site. All material subject to strictly enforced copyright laws.
© 2017 Euromoney Institutional Investor PLC. For help please
see our FAQ.
Switching to MIP International